Credo Technology Group Option Alert: Jan 16 $100 Calls Sweep (6) near the Ask: 300 vs 294 OI; Earnings 3/4 After Close 

Credo Technology Group Option Alert: Jan 16 $100 Calls Sweep (6) near the Ask: 300 @ $18.102 vs 294 OI; Earnings 3/4 After Close Ref=$74.05

Credo Technology Group 株価情報 (NASDAQ: CRDO)

Credo Technology Group (NASDAQ:CRDO) 株価情報

Credo Technology Group

Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.

Credo Technology Group Holding Ltd - Ordinary Shares

Credo Technology Group Holding Ltd

Cerrado Gold Inc

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 90.1% to $2.3 during Tuesday's pre-market session. The market value of their outstanding shares is at $6.7 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares increased by 25.15% to $0.19. The market value of their outstanding shares is at $4.7 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares moved upwards by 23.11% to $0.9. The market value of their outstanding shares is at $46.5 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) shares moved upwards by 21.22% to $14.05. The company's market cap stands at $381.0 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) shares moved upwards by 11.22% to $4.26. The market value of their outstanding shares is at $201.1 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) stock rose 10.49% to $2.21. The market value of their outstanding shares is at $3.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock declined by 91.8% to $0.03 during Tuesday's pre-market session. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) stock decreased by 36.8% to $0.47. The market value of their outstanding shares is at $106.0 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock fell 21.63% to $0.11. The company's market cap stands at $2.6 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares declined by 19.73% to $0.14. The market value of their outstanding shares is at $3.9 million. </li>
<li>Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) stock fell 16.67% to $0.85. The market value of their outstanding shares is at $98.5 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares decreased by 16.59% to $0.35. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ARCT

AXDX

CHRS

CNSP

ENTO

GCTK

KLTO

PLRZ

RDHL

SGMO

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Lichen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) shares rose 54.6% to $5.38 during Tuesday's pre-market session. The company's market cap stands at $3.2 million. </li>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) stock rose 48.15% to $0.37. The market value of their outstanding shares is at $7.8 million. </li>
<li>VirTra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) shares moved upwards by 17.98% to $5.51. The company's market cap stands at $62.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Graphex Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GRFX#AMEX">GRFX</a>) shares rose 17.96% to $0.89. The company's market cap stands at $18.6 million. </li>
<li>Radiant Logistics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RLGT#AMEX">RLGT</a>) shares increased by 13.89% to $7.05. The company's market cap stands at $331.4 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>VCI Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) shares moved upwards by 11.55% to $5.6. The market value of their outstanding shares is at $15.6 million. As per the press release, FY earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Alta Equipment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTG#NYSE">ALTG</a>) stock declined by 51.1% to $2.41 during Tuesday's pre-market session. The company's market cap stands at $79.9 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) shares decreased by 23.14% to $1.96. The market value of their outstanding shares is at $265.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>Lakeside Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSH#NASDAQ">LSH</a>) shares fell 17.61% to $0.89. The company's market cap stands at $6.6 million. </li>
<li>Marwynn Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MWYN#NASDAQ">MWYN</a>) shares declined by 16.18% to $6.01. The company's market cap stands at $102.4 million. </li>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) stock fell 11.37% to $0.12. The market value of their outstanding shares is at $3.5 million. </li>
<li>Perma-Pipe Inlt Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPIH#NASDAQ">PPIH</a>) stock decreased by 11.24% to $12.01. The company's market cap stands at $95.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALTG

GRFX

LICN

MWYN

PPIH

RLGT

VCIG

VSTE

VTSI

WLGS

12 Industrials Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) shares moved upwards by 16.2% to $1.65 during Tuesday's pre-market session. The market value of their outstanding shares is at $114.4 million. </li>
<li>Iveda Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVDA#NASDAQ">IVDA</a>) stock increased by 13.12% to $2.5. The company's market cap stands at $7.0 million. </li>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) stock increased by 10.54% to $3.46. The market value of their outstanding shares is at $34.5 million. </li>
<li>Alpha Modus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMOD#NASDAQ">AMOD</a>) stock rose 10.44% to $1.48. The company's market cap stands at $18.4 million. </li>
<li>Taoping (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>) stock rose 8.13% to $0.32. The company's market cap stands at $4.2 million. </li>
<li>Roadzen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDZN#NASDAQ">RDZN</a>) shares moved upwards by 7.8% to $0.84. The company's market cap stands at $62.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Everspin Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRAM#NASDAQ">MRAM</a>) stock decreased by 13.8% to $5.26 during Tuesday's pre-market session. The market value of their outstanding shares is at $115.5 million. </li>
<li>Exodus Movement (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EXOD#AMEX">EXOD</a>) shares fell 11.61% to $48.0. The company's market cap stands at $1.3 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Indie Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) shares fell 11.39% to $2.34. The company's market cap stands at $458.9 million. The company's, Q1 earnings came out yesterday. </li>
<li>Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) shares declined by 11.35% to $10.24. The company's market cap stands at $2.9 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Abits Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>) shares decreased by 10.29% to $3.4. The company's market cap stands at $8.0 million. </li>
<li>Microvision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) stock fell 9.1% to $1.1. The market value of their outstanding shares is at $270.3 million. As per the press release, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABTS

AMOD

EXOD

GRYP

INDI

IVDA

MLGO

MRAM

MVIS

RDZN

RGTI

TAOP

12 Information Technology Stocks Moving In Tuesday's Pre-Market Session

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) with a Buy and maintains $10 price target.

News

Price Target

Reiteration

Analyst Ratings

FGEN

HC Wainwright & Co. Reiterates Buy on FibroGen, Maintains $10 Price Target

D. Boral Capital analyst Jason Kolbert maintains Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) with a Buy and lowers the price target from $29 to $17.

IMNN

D. Boral Capital Maintains Buy on Imunon, Lowers Price Target to $17

-Reuters, citing sources familiar

Macro Economic Events

Global

Economics

Trump Envoys Steve Witkoff And Keith Kellogg To Travel To Istanbul For Russia-Ukraine Talks

Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.13) by 453.85 percent. This is a 7.69 percent increase over losses of $(0.78) per share from the same period last year.

Earnings

Earnings Misses

ARTL

Artelo Biosciences Q1 EPS $(0.72) Misses $(0.13) Estimate

Biotech

General

SeaStar Medical Reaches Interim Enrollment Target For The NEUTRALIZE-AKI Pivotal Trial Of SCD Therapy In Adult Patients With Acute Kidney Injury

Atossa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is unchanged from the same period last year.

Earnings Beats

ATOS

Atossa Therapeutics Q1 EPS $(0.05) Beats $(0.06) Estimate

In the preceding three months, 4 analysts have released ratings for Microvision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $2.38, along with a high estimate of $3.00 and a low estimate of $2.00. A decline of 4.8% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1747137979_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Microvision. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jesse Sobelson</td>
<td>D. Boral Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$2.50</td>
<td>$3.00</td>
</tr>
<tr>
<td>Casey Ryan</td>
<td>WestPark Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.00</td>
<td>$2.00</td>
</tr>
<tr>
<td>Jesse Sobelson</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Casey Ryan</td>
<td>WestPark Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$2.00</td>
<td>$2.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Microvision. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Microvision compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Microvision's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Microvision's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MVIS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Microvision analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Microvision Better</h2>
Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars.
<h3>A Deep Dive into Microvision's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Challenges: Microvision's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -67.65%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Microvision's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -1888.18%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -54.36%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -29.75%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Microvision's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.06, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Microvision: 4 Analysts Share Their Views

NRXP

HOPE Therapeutics, Inc. And NRx Pharmaceuticals Sign Agreement To Purchase The Kadima Neuropsychiatry Institute; Deal Subject To Satisfaction Of Standard Closing Conditions And Finalization Of Financing, Further Details On The Transaction Will Be Disclosed At That Time

CG Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.41) by 9.76 percent. This is a 25 percent decrease over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $52.00 thousand which missed the analyst consensus estimate of $212.75 thousand by 75.56 percent. This is a 90.17 percent decrease over sales of $529.00 thousand the same period last year.

CGON

CG Oncology Q1 EPS $(0.45) Misses $(0.41) Estimate, Sales $52.00K Miss $212.75K Estimate

Intelligent Bio Solutions Inc. - Common Stock

INBS

Intelligent Bio Solutions Q3 2025 EPS $(0.44) Up From $(1.43) YoY, Sales $728.87K Down From $823.80K YoY

Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and lowers the price target from $60 to $55.

XENE

Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $55

Health Care

Glucotrack Receives Ethical Approval From St. Vincent's Hospital Melbourne Human Research Ethics Committee For Long-Term Clinical Study of Continuous Blood Glucose Monitor

Glucotrack Secures Ethical Approval From St. Vincent's Hospital Melbourne HREC For Long-Term Clinical Study Of CBGM In Participants With Type 1 And Type 2 Diabetes

Chanson International Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHSN#NASDAQ">CHSN</a>) (the "Company" or "Chanson"), a provider of bakery, seasonal, and beverage products through its chain stores in China and the United States, today announced that its self-developed "Songkang Meal" series of nasogastric nutrition formulas has received official registration approval as a Food for Special Medical Purpose ("FSMP") in China. The product has been adopted for use in several hospitals in Xinjiang. As the Company's first FSMP product, "Songkang Meal" represents Chanson's expansion into the medical nutrition and FSMP market, presenting an opportunity for new revenue streams.

CHSN

Chanson International Secures Chinese FSMP Approval For Self-Developed "Songkang Meal" Nasogastric Nutrition Formula, Now Used In Xinjiang Hospitals

Contracts

JFB Construction Holdings Awarded $6.7M Contract As General Contractor For Courtyard By Marriott Conversion And Remodel

D. Boral Capital analyst Jesse Sobelson maintains FiscalNote Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>) with a Buy and maintains $3.75 price target.

NOTE

D. Boral Capital Maintains Buy on FiscalNote Holdings, Maintains $3.75 Price Target

CGNT

Cognyte Wins ~$5M Contract With A Law Enforcement Agency Customer In EMEA Region

Press Releases

Credo Schedules Third Quarter Fiscal Year 2025 Financial Results Conference Call

Credo's PCIe® Retimer Successfully Passes PCI-SIG® Compliance

Credo Reports Third Quarter of Fiscal Year 2025 Financial Results

Credo Showcasing AEC PCIe Products for AI Scaling at NVIDIA GTC 2025

Credo Files AEC Patent Infringement Complaint Against Amphenol, Molex, TE Connectivity, and Volex with United States International Trade Commission

Credo and XConn to Showcase Seamless GPU Cluster at NVIDIA GTC

WPG Americas Accelerates High-Speed Connectivity Solutions through Credo Partnership

Credo to Showcase AI Scale Out Fabric Featuring Credo Optical DSPs at OFC 2025

Credo Named a Winner of the 2025 Top Workplaces USA Award

Credo Unveils the Lark Family - Setting a New Benchmark for Low-Power 800G Optical DSPs

CRDO

Analog Devices

Astera Labs

Advanced Micro Devices, Inc. - Common Stock

Advanced Micro Devices

Arm Holdings plc - American Depositary Shares

ARM Holdings

ASE Technology Holding Co., Ltd. American Depositary Shares (each representing Two Common Shares)

Comments

Credo Technology Group

Unusual Options Activity for

ニュース

パートナーシップ

ベンジンガ・グローバル